Posted by Michael Wonder on 15 Dec 2015
Canada's ERC recommends the funding of Revlimid (lenalidomide) for patients with newly diagnosed multiple myeloma
3 December 2015 - The recommendation is for the use of lenalidomide in combination with low-dose dexamethasone for treatment of newly diagnosed multiple myeloma patients who are not candidates for stem cell transplantation.
For more details, go to: https://www.cadth.ca/revlimid-newly-diagnosed-mm-details
